These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 16219581)
21. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Civallero M; Cosenza M; Marcheselli L; Pozzi S; Sacchi S Expert Opin Investig Drugs; 2012 Nov; 21(11):1597-606. PubMed ID: 22920938 [TBL] [Abstract][Full Text] [Related]
22. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793 [TBL] [Abstract][Full Text] [Related]
23. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643 [TBL] [Abstract][Full Text] [Related]
24. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539 [TBL] [Abstract][Full Text] [Related]
25. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492 [TBL] [Abstract][Full Text] [Related]
26. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Xu Y; Chen SY; Ross KN; Balk SP Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers. Younes A Autophagy; 2008 Jul; 4(5):707-9. PubMed ID: 18469512 [TBL] [Abstract][Full Text] [Related]
28. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109 [TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626 [TBL] [Abstract][Full Text] [Related]
30. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697 [TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688 [TBL] [Abstract][Full Text] [Related]
32. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108 [TBL] [Abstract][Full Text] [Related]
33. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Ong CT; Khoo YT; Mukhopadhyay A; Do DV; Lim IJ; Aalami O; Phan TT Exp Dermatol; 2007 May; 16(5):394-404. PubMed ID: 17437482 [TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Zhao YM; Zhou Q; Xu Y; Lai XY; Huang H Acta Pharmacol Sin; 2008 Apr; 29(4):481-8. PubMed ID: 18358095 [TBL] [Abstract][Full Text] [Related]
36. Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies. Obrador-Hevia A; Fernández de Mattos S; Villalonga P; Rodríguez J Blood Rev; 2009 Sep; 23(5):205-16. PubMed ID: 19362399 [TBL] [Abstract][Full Text] [Related]
37. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268 [TBL] [Abstract][Full Text] [Related]
38. Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Czuczman MS; Leonard JP; Williams ME Clin Adv Hematol Oncol; 2010 Apr; 8(4):A1-14; quiz A15. PubMed ID: 20552750 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs. Gordon IK; Ye F; Kent MS Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974 [TBL] [Abstract][Full Text] [Related]
40. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. Shakir R; Ngo N; Naresh KN J Clin Pathol; 2008 Aug; 61(8):920-7. PubMed ID: 18552173 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]